1Ilan Y,Prakash R,Davidson A,et al.Oral tolerization to adenoviral antigens permits long-term gene expression using recombinant adenoviral vectors[J].J Clin Invest,1997,99(5):1098-1106.
2Gudrun S,Wilhelm B,Sabine H,et al.A hemodynamic response to intravenous adenovirus vector particles is caused by systemic kupffer cell-mediated activation of endothelial cell[J].Hum Gene Ther,2003,14(17):1631-1641.
3Youil R,Toner TJ,Su Q,et al.Comparative analysis of the effect of packaging singal,transgene orientation,promoters,polyadenylation signals,and E3 region on growth properties of first-generation adenoviruses[J].Hum Gene Ther,2003,14(10):1017-1034.
4Liu Q,Anne Z,Pina C,et al.The role of capsid-endothelial interactions in the innate immume response to adenovirus vectors[J].Hum Gene Ther,2003,14(7):627-643.
5Mihara M,Tan I,Chuzhin Y,et al.CTLA4Ig inhibits T cell dependent B-cell maturation in murine systemic lupus erythematosus[J].J Clin Ivest,2000,106(1):91-101.
6DeMatteo RP,Chu G,Ahn M,et al.Long-lasting adenovirus transgene expression in mice through neonatal intrathymic tolerance induction without the use of immunosuppression[J].J Virol,1997,71(7):5330-5335.
7Hayder H,Mullbacher A.Molecular basis of immune evasion strategies by adenoviruses[J].Immunol Cell Biol,1996,74(6):504-512.
8Ilan Y,Droguett G,Chowdhury NR,et al.Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene expression[J].Proc Natl Acad Sci,1997,94(6):2587-2592.
9Everett RS,Hodges BL,Ding EY,et al.Liver toxicities typically induced by first-generation adenoviral vectors can be reduced by use of E1,E2b-deleted adenoviral vectors[J].Hum Gene Ther,2003,14(18):1715-1726.
10Recchia A,Parks RJ,Lamartina S,et al.Site-specific integration mediated by a hybrid adenovirus/adeno-associated virus vector[J].Proc Natl Acad Sci,1999,96(6):2615-2620.
2Hartog H, Wesseling, Boezen HM, et al. The insulin-like growth factor 1 receptor in cancer: old focus, new future [ J ]. Eur J Cancer,2007,43 ( 13 ) : 1895 - 1904.
3Jiang B, Dong H, Zhang Z, et al. Hypoxic response elements con- trol expression of human vascular endothelial growth factor 165 genes transferred to ischemia myocardium in vivo and vitro [ J ]. J Gene Med,2007,9(9) :788 -796.
4Girnita A, Girnita L, del Prete F, et al. Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth [ J ]. Cancer Res,2004,64 ( 1 ) :236 - 242.
5Weidner N. Intratumor microvessel density as a prognostic factor in cancer[ J ]. Am J Pathol, 1995,147 ( 1 ) :9 - 19.
6Bauer G,Dao MA,Case SS,et al. In vivo biosafety model to assess the risk of adverse events from retroviral and lentiviral vectors [J]. Mol Ther,2008,16(7) :1308 - 1315.
7Wang C, Ding C, Kong M ,et al. Tumor - targeting magnetic lipo- plex delivery of short hairpin RNA suppresses IGF-1R overexpres- sion of lung adenocarcinoma A549 cells in vitro and in vivo[ J]. Biochem Biophys Res Commun ,2011,410( 3 ) :537 - 542.
8Piecewicz SM, Pandey A, Roy B, et al. Insulin-like growth factors promote vasculogenesis in embryonic stem cells [ J ]. PLoS One, 2012,7(2) :e32191 -32192.
9Gariboldi MB, Ravizza R, Monti E. The IGFR1 inhibitor NVP- AEW541 disrupts a pro-survival and pro-angiogenic IGF-STAT3- HIFI pathway in human glioblastoma cells [ J ]. Biochem Pharma- eol,2010,80(4) :455 -462.
